Business
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
LONDON & BOSTON, August 06, 2025--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials
About this update from Boston Scientific Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/772dea6c0c7b62b23d9fba061f64d9a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.6Ho1FjQG2YvrvIyKYuG3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/772dea6c0c7b62b23d9fba061f64d9a6","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Former FDA Director David Feigal joins Keyron as Head of Regulatory Affairs","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Dr Joyce Peetermans (ex-Boston Scientific) joins as Acting CTO","length":62,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Christopher Rowland (ex-Boston Scientific) appointed Chairman","length":61,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ForePass aims to replicate metabolic surgery without incisions","length":62,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Preparing for First-In-Human trials after strong large-animal data","length":66,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Head-to-head data showing superiority over $28B/year drug to be published soon","length":78,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":404,"olType":false},{"type":"text","content":"LONDON & BOSTON, August 06, 2025--(BUSINESS WIRE)--Keyron, a pioneer in medical devices for advanced metabolic disease, today announced the appointment of three world-class leaders to its board of directors—including the former Director of the FDA’s Center for Devices and Radiological Health (CDRH) and senior medtech industry leaders with key roles in notable exits within the endoscopy medical device sector. These appointments strengthen Keyron’s regulatory, clinical, and strategic leadership as the company prepares for its upcoming clinical trials, associated global regulatory submissions, and future strategic alliances, centered around its ForePass device. ForePass is designed to replicate the outcomes of metabolic surgery—without cutting, puncturing, or trauma—through a fully reversible, minimally invasive procedure.","length":835,"tagName":"p"},{"type":"text","content":"Board Appoin...